Clinical Trials Browser

Not yet recruiting × Cyclophosphamide × Clear all

NCT07328503 2026-03-18

CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Phase 2 Not yet recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07437963 2026-03-18

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

Phase 1/2 Not yet recruiting

Neuroblastoma, Ganglioneuroblastoma

NCT07444710 2026-03-18

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

Phase 1 Not yet recruiting

Ann Arbor Stage II Mantle Cell Lymphoma

NCT07224672 2026-03-17

ALANIS

Phase 2 Not yet recruiting

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT04579523 2026-03-13

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Phase 1 Not yet recruiting

Multiple Myeloma

NCT07133997 2026-03-13

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

Phase 1 Not yet recruiting

Burkitt Lymphoma

NCT07411599 2026-03-12

Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")

Phase 1/2 Not yet recruiting

Gastrointestinal

Colorectal Cancer, Hereditary Nonpolyposis, Type 6, Carcinoma, Colorectal Neoplasms

NCT07466316 2026-03-12

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

Phase 3 Not yet recruiting

Rhabdomyosarcoma

NCT07164469 2026-03-11

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

Phase 2 Not yet recruiting

Hodgkin Disease

NCT07444632 2026-03-11

Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies

Phase 1 Not yet recruiting

Hodgkin Disease

NCT07463313 2026-03-11

6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors

Phase 2/3 Not yet recruiting

Thymic epithelial tumor, Mediastinal Neoplasms, Thymoma

NCT07304154 2026-03-10

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

Phase 1 Not yet recruiting

Multiple Sclerosis, Myasthenia Gravis, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT05565105 2026-03-03

CD34+ Transplants for Leukemia and Lymphoma

Phase 2 Not yet recruiting

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07441460 2026-03-02

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Phase 3 Not yet recruiting

Resectable HER2-positive Breast Cancer

NCT07416682 2026-02-25

CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms

Phase EARLY_PHASE1 Not yet recruiting

High-risk Plasma Cell Neoplasms

NCT07432178 2026-02-25

CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07428993 2026-02-24

Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma

Phase 2 Not yet recruiting

Osteosarcoma

NCT07423611 2026-02-20

RACE

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07297667 2026-02-13

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Phase 1 Not yet recruiting

BreastGenitourinarySarcoma

Carcinoma, Renal Cell, Sarcoma, Alveolar Soft Part, Triple Negative Breast Neoplasms

NCT07300475 2026-02-13

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Phase 1 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07390539 2026-02-05

B7-H3.CD28Z.CART in CNS Neoplasms

Phase 1 Not yet recruiting

Brain Neoplasms, Ependymoma, Medulloblastoma, Meningeal Neoplasms, Pinealoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT06594939 2026-02-04

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07367685 2026-01-26

Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma

Phase 1 Not yet recruiting

Lymphoma, B-Cell

NCT07358260 2026-01-22

B7-H3.CD28Z.CART in Solid Tumors

Phase 1 Not yet recruiting

Neuroblastoma

NCT07361133 2026-01-22

Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT07349771 2026-01-20

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

Phase 2 Not yet recruiting

Hematopoietic and Lymphatic System Neoplasm

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Phase 1 Not yet recruiting

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT07321912 2026-01-08

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Phase 2 Not yet recruiting

Sarcoma, Ewing, Osteosarcoma

NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

Phase 2 Not yet recruiting

LymphoidOther hematologic neoplasm

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07231250 2025-11-19

Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Phase 2 Not yet recruiting

Dendritic Cell Sarcoma, Interdigitating

NCT07227584 2025-11-12

ALL Backbone in AYAs

Phase 2 Not yet recruiting

LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Phase 1 Not yet recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07199413 2025-09-30

Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases

Phase 1 Not yet recruiting

Brain Neoplasms, Meningeal Carcinomatosis

NCT07193420 2025-09-25

REDUCy

Phase 3 Not yet recruiting

Graft vs Host Disease

NCT06698744 2025-09-23

UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Not yet recruiting

Multiple Myeloma

NCT06986434 2025-09-03

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms

Phase EARLY_PHASE1 Not yet recruiting

Recurrence, Neoplasms, Plasma Cell

NCT07144657 2025-08-27

GastricMALToma

Phase 2 Not yet recruiting

Lymphoma, B-Cell, Marginal Zone

NCT07035379 2025-08-22

A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL

Phase 1/2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07085728 2025-08-22

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

Phase 2 Not yet recruiting

Multiple Myeloma

NCT07105176 2025-08-19

HS-IT101 Injection for Advanced NSCLC

Phase 1 Not yet recruiting

Advanced Non-Small Cell Lung Cancer

NCT07120607 2025-08-13

Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia

Phase 1 Not yet recruiting

Other hematologic neoplasm

Leukemia

NCT07034508 2025-06-24

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

Phase 2 Not yet recruiting

Dendritic Cell Sarcoma, Interdigitating

NCT07024147 2025-06-17

JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma

Phase 1 Not yet recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06996093 2025-05-30

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

Phase 3 Not yet recruiting

Breast Neoplasms

NCT06996119 2025-05-30

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

Phase 1 Not yet recruiting

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06975644 2025-05-22

Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

Phase NA Not yet recruiting

Triple Negative Breast Neoplasms

NCT06939270 2025-04-22

CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors

Phase 1/2 Not yet recruiting

Hypoxia

NCT06921044 2025-04-10

A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06825455 2025-02-13

Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors

Phase EARLY_PHASE1 Not yet recruiting

Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms

NCT06713057 2024-12-03

Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer

Phase 2 Not yet recruiting

Thyroid Neoplasms